The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas

Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However, the pathways of either dopamine or its agonists that lead to the death of cells are incompletely understood and some are e...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoshuang, Tang, Chao, Wen, Guodao, Zhong, Chunyu, Yang, Jin, Zhu, Junhao, Ma, Chiyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357924/
https://www.ncbi.nlm.nih.gov/pubmed/30740089
http://dx.doi.org/10.3389/fendo.2018.00768
_version_ 1783391910927269888
author Liu, Xiaoshuang
Tang, Chao
Wen, Guodao
Zhong, Chunyu
Yang, Jin
Zhu, Junhao
Ma, Chiyuan
author_facet Liu, Xiaoshuang
Tang, Chao
Wen, Guodao
Zhong, Chunyu
Yang, Jin
Zhu, Junhao
Ma, Chiyuan
author_sort Liu, Xiaoshuang
collection PubMed
description Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However, the pathways of either dopamine or its agonists that lead to the death of cells are incompletely understood and some are even conflicting conclusions. The main aim of this paper is to review the different pathways of dopamine and its agonists in prolactinomas to help to gain a better understanding of their functions and drug resistance mechanisms.
format Online
Article
Text
id pubmed-6357924
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63579242019-02-08 The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas Liu, Xiaoshuang Tang, Chao Wen, Guodao Zhong, Chunyu Yang, Jin Zhu, Junhao Ma, Chiyuan Front Endocrinol (Lausanne) Endocrinology Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However, the pathways of either dopamine or its agonists that lead to the death of cells are incompletely understood and some are even conflicting conclusions. The main aim of this paper is to review the different pathways of dopamine and its agonists in prolactinomas to help to gain a better understanding of their functions and drug resistance mechanisms. Frontiers Media S.A. 2019-01-22 /pmc/articles/PMC6357924/ /pubmed/30740089 http://dx.doi.org/10.3389/fendo.2018.00768 Text en Copyright © 2019 Liu, Tang, Wen, Zhong, Yang, Zhu and Ma. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Liu, Xiaoshuang
Tang, Chao
Wen, Guodao
Zhong, Chunyu
Yang, Jin
Zhu, Junhao
Ma, Chiyuan
The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
title The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
title_full The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
title_fullStr The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
title_full_unstemmed The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
title_short The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
title_sort mechanism and pathways of dopamine and dopamine agonists in prolactinomas
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357924/
https://www.ncbi.nlm.nih.gov/pubmed/30740089
http://dx.doi.org/10.3389/fendo.2018.00768
work_keys_str_mv AT liuxiaoshuang themechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas
AT tangchao themechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas
AT wenguodao themechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas
AT zhongchunyu themechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas
AT yangjin themechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas
AT zhujunhao themechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas
AT machiyuan themechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas
AT liuxiaoshuang mechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas
AT tangchao mechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas
AT wenguodao mechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas
AT zhongchunyu mechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas
AT yangjin mechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas
AT zhujunhao mechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas
AT machiyuan mechanismandpathwaysofdopamineanddopamineagonistsinprolactinomas

Ejemplares similares